Volume 138, Issue 5, Pages e3 (May 2010)

Slides:



Advertisements
Similar presentations
Volume 141, Issue 2, Pages e4 (August 2011)
Advertisements

Volume 119, Issue 5, Pages (November 2000)
Volume 143, Issue 3, Pages e1 (September 2012)
The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis  Janneke van Grinsven, Sandra van Brunschot  Gastroenterology 
Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study  Atsushi Kanno, MD, PhD, Atsushi Masamune,
Effect of Eradication of Helicobacter pylori on the Histology and Cellular Phenotype of Gastric Intestinal Metaplasia  Jiro Watari, Koushik K. Das, Peter.
Volume 139, Issue 1, Pages (July 2010)
Volume 144, Issue 5, Pages e10 (May 2013)
Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease  Emma L. Culver, Ross Sadler, Adrian.
Volume 143, Issue 5, Pages (November 2012)
Pancreatic Mass in a Patient With an Increased Serum Level of IgG4
The Use of Immunoglobulin G4 Immunostaining in Diagnosing Pancreatic and Extrapancreatic Involvement in Autoimmune Pancreatitis  Maesha G. Deheragoda,
The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis  Janneke van Grinsven, Sandra van Brunschot  Gastroenterology 
C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice  Belinda Knight, Janina E.E. Tirnitz–Parker,
Long-Term Follow-Up of Autoimmune Pancreatitis: Characteristics of Chronic Disease and Recurrence  Shigeyuki Kawa, Hideaki Hamano, Yayoi Ozaki, Tetsuya.
The Use of Immunoglobulin G4 Immunostaining in Diagnosing Pancreatic and Extrapancreatic Involvement in Autoimmune Pancreatitis  Maesha G. Deheragoda,
Banke Agarwal, Olivia J. Ludwig, Brian T. Collins, Cherise Cortese 
This Month in Gastroenterology
David A. Cano, Shigeki Sekine, Matthias Hebrok  Gastroenterology 
This Month in Gastroenterology
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 153, Issue 2, Pages e3 (August 2017)
Volume 141, Issue 2, Pages (August 2011)
Volume 141, Issue 2, Pages e4 (August 2011)
Genetic Risk Factors for Pancreatic Disorders
Volume 154, Issue 5, Pages (April 2018)
Volume 119, Issue 5, Pages (November 2000)
Volume 139, Issue 1, Pages (July 2010)
Volume 116, Issue 5, Pages (May 1999)
Volume 153, Issue 3, Pages e16-e17 (September 2017)
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Volume 154, Issue 4, Pages (March 2018)
Volume 138, Issue 4, Pages e3 (April 2010)
Volume 136, Issue 2, Pages (February 2009)
Volume 137, Issue 3, Pages (September 2009)
Pancreatic Duct Drainage for the Treatment of a Huge Pancreatic Cyst Associated With Autoimmune Pancreatitis  Hiroyuki Matsubayashi, Toru Matsui, Hiroyuki.
Covering the Cover Gastroenterology
Volume 141, Issue 5, Pages e9 (November 2011)
Marzieh Salehi, Amalia Gastaldelli, David A. D'Alessio 
Volume 134, Issue 4, Pages e2 (April 2008)
Recent Advances in Autoimmune Pancreatitis
Volume 141, Issue 4, Pages e6 (October 2011)
Involvement of the biliary system in autoimmune pancreatitis: a follow-up study  Kenji Hirano, Yasushi Shiratori, Yutaka Komatsu, Natsuyo Yamamoto, Naoki.
Volume 134, Issue 2, Pages e3 (February 2008)
Role of Connective Tissue Growth Factor in Oval Cell Response During Liver Regeneration After 2-AAF/PHx in Rats  Liya Pi, Seh-Hoon Oh, Thomas Shupe, Bryon.
Thomas M. Runge, MD, MPH  Gastrointestinal Endoscopy 
Covering the Cover Gastroenterology
Severe Constipation Clinical Gastroenterology and Hepatology
Volume 141, Issue 3, Pages e1 (September 2011)
Volume 155, Issue 6, Pages (December 2018)
Volume 134, Issue 1, Pages (January 2008)
Maria L. Golson, Kathleen M. Loomes, Rebecca Oakey, Klaus H. Kaestner 
Volume 133, Issue 4, Pages (October 2007)
William D. Leslie  Clinical Gastroenterology and Hepatology 
Volume 133, Issue 4, Pages (October 2007)
Volume 137, Issue 1, Pages e5 (July 2009)
Volume 131, Issue 6, Pages (December 2006)
Volume 137, Issue 5, Pages (November 2009)
Volume 138, Issue 3, Pages e3 (March 2010)
Mark Topazian, Thomas E. Witzig, Thomas C. Smyrk, Jose S
Volume 144, Issue 1, Pages (January 2013)
Volume 132, Issue 2, Pages (February 2007)
Electronic Clinical Challenges and Images in GI
A 27-Year-Old Woman With Constipation: Diagnosis and Treatment
Volume 139, Issue 1, Pages (July 2010)
Volume 139, Issue 6, Pages e1 (December 2010)
Risk of Pancreatitis in Patients With Celiac Disease: Is Autoimmune Pancreatitis a Biologically Plausible Mechanism?  John S. Leeds, David S. Sanders 
Electronic Clinical Challenges and Images in GI
Volume 128, Issue 3, Pages (March 2005)
Volume 151, Issue 2, Pages (August 2016)
Presentation transcript:

Volume 138, Issue 5, Pages 1988-1996.e3 (May 2010) Corticosteroids Correct Aberrant CFTR Localization in the Duct and Regenerate Acinar Cells in Autoimmune Pancreatitis  Shigeru B.H. Ko, Nobumasa Mizuno, Yasushi Yatabe, Toshiyuki Yoshikawa, Hiroshi Ishiguro, Akiko Yamamoto, Sakiko Azuma, Satoru Naruse, Kenji Yamao, Shmuel Muallem, Hidemi Goto  Gastroenterology  Volume 138, Issue 5, Pages 1988-1996.e3 (May 2010) DOI: 10.1053/j.gastro.2010.01.001 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 (A) Pancreatic exocrine function in AIP was examined by the secretin test. Tests were performed at the time of diagnosis (0 months), 3 months, and 12 months after initiation of corticosteroids. Lower limits of normal are marked by dashed lines. Black lines indicate change of exocrine function in patients whose function was evaluated at 0 and 3 months after initiation of corticosteroids. Gray lines indicate changes of exocrine function in patients whose exocrine function was evaluated at 0, 3, and 12 months. (a) Total secreted volume for an hour (normal, ≥183 mL/h). (b) Maximum HCO3− concentration (mbc) (normal, ≥80 mEq/L). (c) Total amylase output for an hour (normal, ≥99,000 U/h). (B) Change in pancreatic exocrine functions caused by short-term treatment. (a) Secreted volume was not altered by steroids (n = 8, mean ± standard error of the mean; at 0 months, 123.5 ± 12.9 mL/h; at 3 months, 122.1 ± 12.7 mL/h). (b) MBC (n = 7; at 0 months, 53.3 ± 5.8 mEq/L; at 3 months, 72.5 ± 7.2 mEq/L), and (c) total amylase output (n = 8; at 0 months, 6138 ± 2107 U/h; at 3 months, 17,143 ± 2710 U/h) were improved significantly by treatment. (C) Change of pancreatic exocrine functions at 0, 3, and 12 months after initiation of corticosteroids (n = 3). (a) Secretory volume and (b) MBC were not altered by prolonging treatment up to 12 months. (c) Amylase output is improved by short-term treatment (at 0 months, 6683 ± 444 U/h; at 3 months, 17,200 ± 1968 U/h) and further by long-term treatment (at 12 months, 28,962 ± 4894 U/h). Gastroenterology 2010 138, 1988-1996.e3DOI: (10.1053/j.gastro.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Pancreatic sections were stained with H&E. (A) Normal subject. (B) AIP, surgically resected tissue. Masson's trichrome staining of (C) normal pancreas and (D) AIP. H&E staining of specimen (E) before and (F) 3 months after initiation of steroid treatment. (E and F) Sections were obtained from the same patient. Bars, 100 μm. Insets show images at a higher magnification. Gastroenterology 2010 138, 1988-1996.e3DOI: (10.1053/j.gastro.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Immunolocalization of AQP1 in the pancreas. (A) Control subject. (B) AIP, surgically resected. Biopsy specimen (C) before treatment and (D) after treatment. (C and D) Sections were obtained from the same patient. The pathologic changes were seen in all sections examined. Bars, 20 μm. Insets show images at a higher magnification. Gastroenterology 2010 138, 1988-1996.e3DOI: (10.1053/j.gastro.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 Immunolocalization of CFTR in the pancreas. (A) Normal subject. (B) AIP, surgically resected. Biopsy specimen (C) before and (D) after treatment. (C and D) Sections are from the same patient. (E) Pancreatic sections obtained from normal subjects (n = 4), from AIP patients at 0 (n = 7) or 3 months (n = 7) treatment were scored at 0 (none), 1 (slight), 2 (moderate), and 3 (severe) for the degree of cytoplasmic staining of CFTR in pancreatic ducts. CFTR localization also was examined in the pancreas from the patients with (F) alcoholic, (G) obstructive, and (H) idiopathic chronic pancreatitis. Each panel represents 6 alcoholic, 2 obstructive, and 3 idiopathic cases of pancreatitis, respectively. Bars, 20 μm. Insets show images at a higher magnification. Gastroenterology 2010 138, 1988-1996.e3DOI: (10.1053/j.gastro.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 5 Immunohistochemical staining for IgG4. (A) Marked IgG4-positive plasma cell infiltrates are present in tissue before treatment. (B) The number of IgG4-positive plasma cells was decreased significantly after treatment. (C) Pancreatic sections obtained from normal subjects (n = 4), and AIP patients at 0 (n = 7) or 3 months (n = 7) treatment were scored at 0 (none), 1 (slight), 2 (moderate), and 3 (severe) for extent of IgG4-positive plasma cell infiltration. Gastroenterology 2010 138, 1988-1996.e3DOI: (10.1053/j.gastro.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions

Figure 6 Immunoperoxidase labeling of CD133 (prominine-1) in the pancreas. (A) Normal subject. (B) Absence of acinar cells and massive fibrosis are evident before treatment. CD133 was detected in the apical membrane of residual pancreatic ducts. (C) CD133 and fibrosis after short-term steroid treatment. (D) CD133-positive cells are absent and acinar cell regeneration did not occur. Bars, 20 μm. Insets show images at a higher magnification. Gastroenterology 2010 138, 1988-1996.e3DOI: (10.1053/j.gastro.2010.01.001) Copyright © 2010 AGA Institute Terms and Conditions